The treatment of angelic syndrome ushers in a new breakthrough! FDA Grants OV101 Orphan Drug Title
-
Last Update: 2020-07-14
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Angel icing syndrome is a disease caused by a genetic defectChildren with the disease often have a smile on their face, lack of language skills, hyperactivity, and low intelligenceAbout 80% of patients haveepilepsysymptoms, about 50% have microcephalyThe cause of angelic syndrome is a defect in the 15q part of the imprinting gene region of chromosome 15 from the mother, or two chromosome 15s from the father with this defectangelic syndrome is associated with a decrease in the effect of strong straightening inhibition, a function of selective GABAareceptor, which enables the human brain to correctlyinterpretation ofexcitability and inhibition nerve signalsBiopharmaceutical company Ovid Therapeutics recently announced that the U.SFDAhas awarded OV101 (gaboxadol) orphan drug title to treat angel icing syndromeOV101 is considered to be the only selective GABAa receptor agonist under development and is currently undergoing a critical Phase III NEPTUNE trial, the main results of which are expected to be announced in the fourth quarter of 2020 "OV101 has the potential to become the first FDA-approved treatment for angelic human syndrome," said Amit Rakhit, M.D., President and Chief Medical Officer of Ovid Therapeutics Getting the orphan drug designation from the FDA is an important milestone for Ovid With this designation, we are eligible for FDA priority review rights."
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
